Feb 12, 2025 · Enhertu is a treatment for breast cancer, advanced stomach cancer, non-small cell lung cancer, and solid tumors with HER2 gene mutations in certain patients. Enhertu may help …

have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer. whose disease has returned during or within 6 months of …

NCCN Guidelines ® lists fam-trastuzumab deruxtecan-nxki (ENHERTU) as a treatment option for multiple metastatic solid tumors. See the NCCN Guidelines for detailed information.

Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) can be used to treat unresectable or metastatic HER2-positive breast cancer.

Jan 31, 2025 · Enhertu is an infusion given into your vein (IV) by your healthcare provider. What is Enhertu used for? Enhertu (fam-trastuzumab deruxtecan-nxki) is commonly used for treating …

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to …

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based …

Jul 2, 2024 · Enhertu is a brand-name intravenous (IV) infusion prescribed for certain types of HER2-positive cancers and HER2-low breast cancer. Enhertu contains the active ingredient …

Aug 5, 2024 · Enhertu (fam-trastuzumab deruxtecan-nxki) is used to treat adults with certain cancers that have a protein called HER2 on tumor cells. These cancers include breast cancer, …

Learn about the side effects of Enhertu (fam-trastuzumab deruxtecan), from common to rare, for consumers and healthcare professionals.